

**REMARKS/ARGUMENTS**

In response to the restriction requirement mailed October 5, 2005, Applicant elects Group II, claims 16-18, without traverse. New claims 19-21 depend from claim 16 and are in the elected group.

The elected claims are directed to cells made by a biotechnological process encompassed by the method of claims 1-15. Under the provisions of 35 U.S.C. 103(b) claims 1-15 should be rejoined and allowed upon determination that the cells of claims 16-21 are novel and nonobvious.

Claim 16 has been amended to make it independent and to incorporate elements of original claim 1. Claim 17 is amended to correct a grammatical error. New claim 19 finds support in the specification and in original claim 10. New claim 20 finds support in the specification and in original claim 2. New claim 21 finds support in the specification and in original claims 6, 8 and 12.


**CONCLUSION**

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Date: December 21, 2005

Respectfully submitted,

  
Randolph Ted Apple  
Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 415-576-0300  
Attachments  
RTA:sej  
60663776 v1